Article

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.

Department of Haematology,Imperial College Academic Health Science Centre, Hammersmith Hospital, Du Cane Rd., London, UK.
British Journal of Haematology (Impact Factor: 4.94). 03/2011; 153(2):179-90. DOI: 10.1111/j.1365-2141.2011.08603.x
Source: PubMed

ABSTRACT Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the technique is most appropriate for patients who have achieved complete cytogenetic remission and can be used to define specific therapeutic milestones. To achieve this effectively, standardization of the laboratory procedures and the interpretation of results are essential. We present here consensus best practice guidelines for RT-qPCR testing, data interpretation and reporting that have been drawn up and agreed by a consortium of 21 testing laboratories in the United Kingdom and Ireland in accordance with the procedures of the UK Clinical Molecular Genetics Society.

0 Bookmarks
 · 
146 Views

Full-text

View
140 Downloads
Available from
May 31, 2014